Curcuma longa Standardised for Nanocurcumin® and Boswellia serrata in Osteoarthritis-Related Joint Symptoms: A Critical Narrative Review and Evidence Appraisal of Biotex Curcuma + Boswellia Capsules

Abstract

Osteoarthritis (OA) is a disorder of the entire synovial joint in which pain, stiffness, and impaired function arise from interacting cartilage, synovial, subchondral-bone, inflammatory, and nociceptive processes. This critical narrative review evaluates Curcuma longa and Boswellia serrata evidence relevant to the Biotex Curcuma + Boswellia capsule, whose current label declares 150 mg C. longa rhizome (Rz) standardised for Nanocurcumin® and 150 mg B. serrata bark (Bk; Salai Guggul) per capsule. Nanocurcumin® is curcumin presented through a nano-enabled delivery approach rather than a different pharmacologically active molecule; accordingly, the established biochemical targets and ingredient-level evidence for curcumin are directly relevant to its curcumin payload, while formulation technology determines exposure and dose efficiency. Human pharmacokinetic studies and systematic reviews demonstrate that advanced curcumin delivery systems can raise systemic exposure many-fold relative to native curcumin, providing a strong scientific basis for lower-dose delivery-enhanced curcumin strategies. Randomised trials and meta-analyses report symptom benefits with several Curcuma/curcumin preparations and standardised Boswellia extracts in OA, and clinical studies of other Curcuma–Boswellia combinations provide additional support for the combination concept. The evidence therefore gives the Biotex formulation a favourable, evidence-aligned joint-support rationale, particularly through the Nanocurcumin® active moiety and complementary botanical pharmacology. Product-specific randomised and pharmacokinetic studies would define the precise magnitude of benefit, bioavailability enhancement, and dose equivalence for the marketed capsule.